Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

hereditary edema KVD818 kalvista protease inhibitor

News and Trends 11 Aug 2016

New First-in-Human trial for rare Hereditary Angioedema begins in the UK

A new drug by KalVista is starting a Phase I trial. The drug could become a preventive treatment for people suffering for hereditary angioedema, a rare genetic condition that can be life-threatening. Based in the Tetricus Science Park (UK), KalVista targets proteases that are involved in diseases. It develops small molecule inhibitors for plasma kallikrein, an enzyme involved […]

August 11, 2016 - 2 minutesmins - By Denise Neves Gameiro

astrazeneca phase III failure nsclc selumetinib

News and Trends 11 Aug 2016

This new Phase III Failure adds up to AstraZeneca’s Troubles

AstraZeneca’s oncology pipeline takes a hit, as one of its Phase III trials failed to meet its primary endpoint. The program targeted advanced non-small lung cancer. It looks like it’s up to immunotherapies now. Now struggling for a while, AstraZeneca has been refocusing on cancer and investing big in new candidates. The strategy hasn’t yet […]

August 11, 2016 - 3 minutesmins - By Denise Neves Gameiro

amazon synthetic dna helixworks indiebio

News and Trends 10 Aug 2016

Why on Earth would someone order DNA on Amazon?

Yes, you can now add a customized genetic sequence to your shopping cart, thanks to a Biotech startup. But what would you need it for? Let’s say, you are buying some really cool Biotech reading material online. You can now head to the ‘Industrial & Scientific’ section of Amazon and get a GeneSlice with that. For […]

August 10, 2016 - 4 minutesmins - By Denise Neves Gameiro

rheumatoid arthritis anti il 6r ablynx abbvie

News and Trends 9 Aug 2016

Ablynx’ Best-In-Class Antibody might not be that ‘Compelling’ to Abbvie

Ablynx has disclosed ‘compelling’ results for its Phase IIb trial in rheumatoid arthritis. But it might have a hard time compelling AbbVie to pay €68M to continue the candidate’s development, as the grass is not as green as it seems… Ablynx‘s impressive list of big Pharma collaborations could soon need an update, as its $840 partnership with […]

August 9, 2016 - 3 minutesmins - By Denise Neves Gameiro

rio olympics 2016 biotech doping

News and Trends 9 Aug 2016

Yes, Biotech can help you win the Olympic Games of Rio

The world’s eyes are set on the 2016 edition of the Summer Olympics, which started in Rio de Janeiro last week. I had a look at how Biotech has been involved in the Olympics – and how it could define it in the future. The Summer Olympics of 2016 have been marked by its fair […]

August 9, 2016 - 5 minutesmins - By Denise Neves Gameiro

sleep homeostasis sandman channel oxford cncb

News and Trends 8 Aug 2016

The Brain’s Sleep Switch was just discovered, zZz …

Researchers from the University of Oxford have discovered how certain neurons control when we go to sleep. The biology behind it involves an ion channel that reacts to the ‘happy chemical’ dopamine, changing places in the neurons. Sleep is essential to health, with the Center for Disease Control even calling insufficient sleep a public health […]

August 8, 2016 - 3 minutesmins - By Denise Neves Gameiro

ADVERTISEMENT

endometriosis treatment womens health biotech

News and Trends 8 Aug 2016

A €580M Collaboration for Endometriosis Therapies breaks into Clinical Development

Update (24/07/2017): Bayer and Evotec have announced a second compound from their partnership made it to clinical trials in humans. Consequently, they have decided to extend the partnership for an extra year and develop 4 candidates instead of the original 3. Originally published on 08/08/2016 An endometriosis therapy is now moving to clinical development. It’s […]

August 8, 2016 - 3 minutesmins - By Denise Neves Gameiro

ff pharma map biotech of the week

News and Trends 5 Aug 2016

Dutch FF Pharma has a Promising Immunotherapy to fight Crohn’s Disease

Arrivederci Italia! We’re going to fly up to the Netherlands for another Biotech-related adventure! This time, we’re visiting Utrecht, the fourth most populated city in the country and home-base to FF Pharma, our Biotech of the Week! City: Utrecht (The Netherlands) Founded: 2012 Employees: N/A Financial Data: €4M Total Raised (as of 12/2015) CEO: Mark De Boer Mission: FF […]

August 5, 2016 - 2 minutesmins - By Joachim Eeckhout

roche inovio hbv immunotherapy vaccine

News and Trends 4 Aug 2016

Roche drops Partnership for Hepatitis Immunotherapy

While everybody wants to get the next immunotherapy on the market, Roche is turning its back on one. It’s leaving the partnership with Inovio, which focuses on developing a DNA-based immunotherapy to treat Hepatitis B. Previously, Roche has left projects to focus on immunotherapies, particularly in the hype field of immuno-oncology. This was an important […]

August 4, 2016 - 3 minutesmins - By Denise Neves Gameiro

pharmamar pm1183 small cell lung cancer

News and Trends 4 Aug 2016

Marine Drug goes to Phase III trials to treat Lung Cancer

PharmaMar is starting a new Phase III trial, with patients suffering from small cell lung cancer (SCLC). It’ll test the efficacy of its third candidate obtained from marine organisms (PM1183) as a SCLC treatment. PharmaMar is one of the hot Biotechs in Spain, which just saw its second drug finish Phase III trials with good results (and is […]

August 4, 2016 - 2 minutesmins - By Denise Neves Gameiro

cambridge famin C13orf31 macrophage metabolism

News and Trends 3 Aug 2016

Mysterious Immunology Mechanism Unlocked thanks to CRISPR

While studying a mutation connected to inflammatory disease, researchers from the University of Cambridge have found a previously unknown mechanism in immune response. As the cost of NGS plummets, genetic data is growing massively. With the help of bioinformatics, information about genetic variants and mutations can be linked to diseases. Sophia Genetics (Switzerland), Diploid (Belgium) […]

August 3, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 3 Aug 2016

UPDATED: TiGenix finishes Phase III Stem Cell therapy to treat Crohn’s disease

Belgium is a real pioneer in developing stem cell therapies. TiGenix pushes this precursor position even further by presenting good results from a Phase III of its stem cell therapy (Cx601) treating Crohn’s disease. UPDATE (article originally published on 24/8/2015): TiGenix’s Phase III results were now published in The Lancet. Julián Panés, the global coordinator […]

August 3, 2016 - 3 minutesmins - By Philip Hemme

ADVERTISEMENT